Media

The University of Hong Kong (HKU) will start a large-scale clinical trial on a new COVID-19 inactivated vaccine (Omicron variant) developed by China National Biotec Group (Sinopharm). Led by Professor Ivan Hung, Chief of Division of Infectious Diseases and Clinical Professor of Department of Medicine, LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and with the coordination and technical support by HKU Clinical Trials Centre (HKU-CTC), the study aims to evaluate the investigational vaccine’s safety and immune response as a booster for adults, and will last for around a year. 1,800 adult volunteers who have already received two or three doses of inactivated or mRNA COVID-19 vaccines will be recruited to take part in the study.

A press conference will be held tomorrow (May 31, Tuesday) to share the details of the clinical trial.

Media representatives are cordially invited to attend the press conference. Details are as follows:-

Date:               May 31, 2022 (Tuesday)
Time:              1:00pm (Media reception starts at 12:45pm)
Venue:            Cheung Kung Hai Lecture Theatre 3-4, William Mong M.W. Building,
                        LKS Faculty of Medicine, ​The University of Hong Kong,
                        21 Sassoon Road, Pokfulam, Hong Kong

Guests:
(HKU)
Professor Ivan Hung, Ru Chien and Helen Lieh Professor in Health Sciences Pedagogy, Chief of Division of Infectious Diseases and Clinical Professor of Department of Medicine, School of Clinical Medicine, HKUMed
Dr. Kelvin To, Chairperson and Clinical Associate Professor of Department of Microbiology, School of Clinical Medicine, HKUMed
Mr. Henry Yau, Managing Director, Clinical Trials Centre, HKUMed

(China National Biotec Group, Sinopharm)
Professor Yang Xiaoming, Chairman, China National Biotec Group, Sinopharm
Professor Zhang Yuntao, Chief Scientist, China National Biotec Group, Sinopharm

For media enquiries, please contact Ms. Cathy Shen of HKU-CTC (Tel: 2255 2553; Email: cathyswi@hku.hk)